Nodal Spread Reaches 19.2% in Early-Onset T1 Colorectal Cancer

A T1 colorectal tumor is the kind a screening colonoscopy is meant to catch, and the decision that follows is whether removing the lesion is enough or whether the lymph nodes have to come out too. In surgically treated patients, that calculation looks different under age 50: nodal metastasis reached 19.2% in early-onset disease against 11.1% in patients 50 and older.¹

A Rising Population Without a Guideline

Roughly 10% of colorectal cancers now occur in people younger than 50 years, and the incidence in that group has been climbing about 1.4% annually. The broader pattern extends across gastrointestinal malignancies, with esophageal, gastric, liver, pancreatic, and biliary cancers all showing rising early-onset incidence attributed variously to lifestyle, hereditary, and environmental factors.²

As screening ages come down, more of these cancers will be caught at T1, where roughly 10% of all patients harbor nodal disease and where age has not historically been counted among the recognized risk factors alongside deep submucosal invasion, poor differentiation, lymphovascular invasion, and high-grade tumor budding. No guideline currently addresses early-onset T1 disease specifically, and the one body that has taken a position, the European Hereditary Tumor Group, concluded there was insufficient evidence to manage it differently.¹

The current meta-analysis searched PubMed/MEDLINE, SCOPUS, the Cochrane Library, Web of Science, and ICHUSHI for studies published through the end of 2024. Of 1214 records, 10 studies yielding 11 databases met criteria. The primary analysis, however, used 6 non-overlapping databases from 5 studies covering 29,132 patients, of whom 2759 (9.4%) were younger than 50 years at diagnosis.

Every included patient had undergone surgical resection with lymph node dissection, which is the analysis's defining constraint. Six of the studies were case-control and 4 retrospective cohorts; 8 drew on registries, and 3 on single institutions, and the risk of confounding was judged serious in 3 because they ran no multivariable adjustment.

An 8-Point Absolute Gap, Consistent Across Datasets

Pooled nodal metastasis rates came to 19.2% (95% CI, 17.8%-20.6%) in early-onset T1 disease and 11.1% (95% CI, 10.7%-11.5%) in late-onset, an absolute difference of about 8 percentage points against an overall T1 rate of 11.9% (95% CI, 11.5%-12.2%). Early-onset disease carried higher odds of nodal metastasis (OR, 1.94; 95% CI, 1.75-2.15), and all of the 6 databases pointed in the same direction with no heterogeneity detected.

Sensitivity analyses held. Excluding Surveillance, Epidemiology, and End Results Program data entirely gave an OR of 2.02 (95% CI, 1.67-2.44), and adding back a study restricted to low-risk patients gave an OR of 1.95 (95% CI, 1.76-2.16). Where individual studies had run multivariable models, younger age kept trending toward higher odds even after adjustment, with patients younger than 50 years carrying an adjusted OR of 2.17 (95% CI, 1.75-2.70) against those aged 80 and older.

Clinicopathologic differences did not obviously explain the gap. Women made up a slightly but significantly higher share of the early-onset group, and female sex has been linked to nodal risk in T1 disease before. Tumor grade, size, invasion depth, and lymphovascular invasion showed no significant differences between age groups.

Why the Authors Will Not Call Age Independent

“Accordingly, it cannot be concluded that younger age is an independent risk factor for LNM,” the authors wrote, using the abbreviation for lymph node metastasis.

They reason that none of the 4 studies with multivariable models included every established predictor; each omitted at least 1 of invasion depth, tumor grade, budding grade, or lymphovascular invasion. Lymphovascular invasion entered as a covariate in only 2, and genetic factors in 1. Access to care, income, and treatment selection could also act as confounders and were not captured anywhere.

The restriction to surgically treated patients with pathologically evaluable nodes matters just as much, because it likely inflates the absolute rates and makes them a poor guide to the overall T1 population or to low-risk lesions managed endoscopically. The evidence base is retrospective throughout, and excluding studies that used age cutoffs other than 50 may itself have introduced selection bias.

What survives those caveats is a consistent signal in nearly 30,000 patients that argues for individualized follow-up rather than a change in resection thresholds. Routine computed tomography is not mandatory after stage I disease, and this analysis measured nodes at surgery rather than recurrence or survival, so it cannot justify adding imaging on its own. For a younger patient weighing endoscopic resection alone against added surgery, however, an 8-point absolute difference is the kind of number that belongs in the conversation.

References

1. Fukuda H, Hayashi Y, Yoneda S, et al. Risk of lymph-node metastasis in early onset T1 colorectal cancer: a systematic review and meta-analysis. J Gastroenterol. 2026;61(8):1068-1082. doi:10.1007/s00535-026-02465-7

2. Vishwanath A, Krishna S, Manudhane AP, Hart PA, Krishna SG. Early-onset gastrointestinal malignancies: an investigation into a rising concern. Cancers (Basel). 2024;16(8):1553. doi:10.3390/cancers16081553